Kovitz Investment Group Partners LLC Sells 40,925 Shares of Moderna, Inc. (NASDAQ:MRNA)

Kovitz Investment Group Partners LLC trimmed its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 83.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,838 shares of the company's stock after selling 40,925 shares during the quarter. Kovitz Investment Group Partners LLC's holdings in Moderna were worth $326,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Principal Financial Group Inc. increased its stake in Moderna by 4.2% during the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company's stock valued at $25,359,000 after buying an additional 15,218 shares during the period. GAMMA Investing LLC increased its stake in shares of Moderna by 31.9% during the fourth quarter. GAMMA Investing LLC now owns 3,173 shares of the company's stock valued at $132,000 after acquiring an additional 768 shares during the period. Douglas Lane & Associates LLC raised its holdings in Moderna by 62.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company's stock worth $32,175,000 after purchasing an additional 298,715 shares in the last quarter. Czech National Bank increased its position in shares of Moderna by 6.6% during the 4th quarter. Czech National Bank now owns 73,424 shares of the company's stock valued at $3,053,000 after purchasing an additional 4,526 shares during the period. Finally, Green Alpha Advisors LLC grew its stake in shares of Moderna by 54.9% in the 4th quarter. Green Alpha Advisors LLC now owns 16,900 shares of the company's stock worth $703,000 after purchasing an additional 5,987 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Stock Up 0.8 %

Shares of MRNA stock traded up $0.23 during trading hours on Monday, reaching $27.84. 7,799,065 shares of the company's stock were exchanged, compared to its average volume of 7,425,602. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The stock has a market capitalization of $10.76 billion, a P/E ratio of -3.00 and a beta of 1.99. The business has a fifty day moving average price of $29.52 and a 200-day moving average price of $37.34.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. During the same period in the prior year, the firm earned ($3.07) EPS. The business's revenue was down 35.3% on a year-over-year basis. As a group, research analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on MRNA shares. Bank of America dropped their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Royal Bank of Canada reduced their price objective on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research note on Friday. Morgan Stanley dropped their target price on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. JPMorgan Chase & Co. reduced their price target on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Friday, March 21st. Finally, William Blair reiterated a "market perform" rating on shares of Moderna in a research report on Thursday, April 17th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $53.95.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.